Observational studyEuropean heart journal2024
New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry.
Observational study in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Oral anticoagulant monotherapy versus oral anticoagulant plus antiplatelet therapy in adults with stable coronary artery disease.The Cochrane database of systematic reviews · 2026Article
- Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.Current cardiology reports · 2026Review
- C-Reactive Protein-to-Albumin Ratio (CAR) and Left Atrial Diameter Predicts New-Onset Atrial Fibrillation in Chronic Coronary Syndrome: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Prevalence, associated factors, and prognostic value of P wave abnormality in patients with coronary artery disease.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Usefulness of the AHEAD score for prediction of all-cause death in patients with acute and chronic coronary syndromes.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Atrial Fibrillation as an Independent Predictor of Myocardial Ischemia.Medicina (Kaunas, Lithuania) · 2025Article
- Left atrial function during exercise stress echocardiography as a sign of paroxysmal/persistent atrial fibrillation.Cardiovascular ultrasound · 2024Article
- Spectrum of Non-Obstructive Coronary Artery Disease and Its Relationship with Atrial Fibrillation.Journal of clinical medicine · 2024Review
- Myeloperoxidase and its derivative hypochlorous acid combined clinical indicators predict new-onset atrial fibrillation in sepsis: a case-control study.BMC cardiovascular disorders · 2024Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsData on new-onset atrial fibrillation (NOAF) in patients with chronic coronary syndromes (CCS) are scarce. This study aims to describe the incidence, predictors, and impact on cardiovascular (CV) outcomes of NOAF in CCS patients.
methodsData from the international (45 countries) CLARIFY registry (prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) were used. Among 29 001 CCS outpatients without previously reported AF at baseline, patients with at least one episode of AF/flutter diagnosed during 5-year follow-up were compared with patients in sinus rhythm throughout the study.
resultsThe incidence rate of NOAF was 1.12 [95% confidence interval (CI) 1.06-1.18] per 100 patient-years (cumulative incidence at 5 years: 5.0%). Independent predictors of NOAF were increasing age, increasing body mass index, low estimated glomerular filtration rate, Caucasian ethnicity, alcohol intake, and low left ventricular ejection fraction, while high triglycerides were associated with lower incidence. New-onset atrial fibrillation was associated with a substantial increase in the risk of adverse outcomes, with adjusted hazard ratios of 2.01 (95% CI 1.61-2.52) for the composite of CV death, non-fatal myocardial infarction, or non-fatal stroke, 2.61 (95% CI 2.04-3.34) for CV death, 1.64 (95% CI 1.07-2.50) for non-fatal myocardial infarction, 2.27 (95% CI 1.85-2.78) for all-cause death, 8.44 (95% CI 7.05-10.10) for hospitalization for heart failure, and 4.46 (95% CI 2.85-6.99) for major bleeding.
conclusionsAmong CCS patients, NOAF is common and is strongly associated with worse outcomes. Whether more intensive preventive measures and more systematic screening for AF would improve prognosis in this population deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.